Covidien spins out $2.1bn Mallinckrodt pharma business
This article was originally published in Clinica
Executive Summary
Covidien has completed the spin-out of its 5,500-employee pharma business, making Mallinckrodt Pharmaceuticals an official stand-alone concern with more than $2 billion in annual net sales.